HOME >> MEDICINE >> NEWS
ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

RICHMOND, CALIF. (Monday, May 18, 1998) --- Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) today reported results from two Phase II studies of its lead anticancer viral therapeutic, ONYX-015, in patients with tumors of the head and neck. In an ongoing Phase II study combining ONYX-015 with standard chemotherapy, the company reported that nine out of ten patients with recurrent tumors have experienced tumor regressions of greater than 50 percent to date, with two patients experiencing complete responses. In addition, the company reported that 30 percent of patients treated with ONYX-015 alone had significant tumor regressions, including two complete regressions in patients with end-stage, treatment-resistant disease.

During a poster session today at the American Society of Clinical Oncology (ASCO) meeting in Los Angeles, Onyx presented interim results from a Phase II trial combining ONYX-015 with Cisplatin and 5-FU, two standard chemotherapeutic agents used in the treatment of head and neck cancers. In addition to the two patients who had complete responses, seven patients experienced between 50 and 95 percent reductions in tumor mass. The one remaining patient has experienced a 40 percent tumor regression. To date, all of the patients continue on treatment with no evidence of disease progression. The average overall response rate with Cisplatin and 5-FU alone is about 35 percent historically in patients with recurrent disease,noted David H. Kirn, M.D., director of clinical research at Onyx.

"We have seen significant tumor regression in the patients treated to date, including some complete responses, and this is a dramatic early finding," Dr. Kirn said. "But we have only evaluated ten patients at this point. While we are encouraged by these initial results, we remain cautiously optimistic."

"Of course, because this is an ongoing study, we do not yet have information regarding durability of responses. We will be able to discuss these findings with gre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415/ 821-2413
Kureczka/Martin Associates
18-May-1998


Page: 1 2 3

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
8. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
9. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
Cached News: